The World Is Breaking. Here's What I'm Doing.
What's coming for The Clinical Edge in 2026
To read our full disclaimer, click here.
The world is fracturing.
Geopolitical tensions that have been simmering for years are now boiling over.
Trade wars. Currency instability. Escalating conflicts across multiple continents.
Central banks are out of ammunition. Governments are drowning in debt.
The social contract that underpinned decades of relative stability feels like it’s unravelling in real time.
Every headline screams crisis.
Energy security. Food security. Supply chains that snap without warning.
A cost-of-living squeeze that’s crushing households.
Political extremism rising on every front.
And markets? They’re pretending everything is fine.
Until they’re not.
2026 could be the year it all comes undone…
But here’s what most investors miss.
While the macro picture looks terrifying, one sector has quietly proven itself over and over again - through wars, recessions, pandemics, and every other crisis the modern world has thrown at it.
Healthcare.
People get sick regardless of who’s in power.
Diseases don’t care about interest rates. Clinical trials don’t pause because of tariffs. Drug approvals happen whether markets are up or down.
Healthcare operates on its own timeline.
Look at the data. Through the dot com bubble, 2008 financial crisis, the COVID collapse, the 2022 rate shock - healthcare companies with real products and real revenue kept operating, kept innovating, kept compounding.
It’s not a coincidence.
Healthcare has something most sectors don’t: inelastic demand.
Ageing populations. Regulatory moats that take decades to build. Pricing power backed by genuine clinical outcomes.
When everything else is correlated and falling apart, healthcare often isn’t.
Now add AI to the equation.
The convergence happening right now between artificial intelligence and healthcare is unlike anything we’ve seen before.
Drug discovery timelines that used to take a decade are being compressed to years.
Diagnostic accuracy is exceeding human capabilities in specific applications.
Personalised medicine is moving from concept to clinical reality.
The companies that figure out how to deploy AI effectively in healthcare - particularly in diagnostics, drug development, and operational efficiency - aren’t just going to survive 2026.
They’re going to define the next decade.
This isn’t hype.
It’s already happening.
And the market is barely paying attention to the small players doing it.
Which brings us to microcaps.
The real asymmetry isn’t in mega-cap pharma trading at 20x earnings.
It’s in the overlooked, misunderstood, left-for-dead healthcare companies trading at enterprise values smaller than a London flat.
These are the companies that fail screens. That confuse analysts. That look broken on the surface.
But underneath? Platform technologies. Regulatory approvals that took years to secure. Insider ownership where management’s wealth is on the line. Multiple shots on goal across different indications, geographies, or business lines.
While everyone else is paralysed by headlines, the smart money is positioning in the spaces no one else is looking.
Small healthcare companies with mispriced optionality and asymmetric upside.
The Clinical Edge in 2026
This year, the page is scaling up.
More ideas. The goal is 2+ new thesis posts per month. More companies. More optionality. More shots on goal.
Real-time updates. Existing thesis will get ongoing coverage as catalysts hit - earnings, trial results, regulatory decisions, management changes. The story doesn’t end at publication.
Management access. This is the big one. In 2026, the aim is to get direct interviews with the management teams behind the companies covered here. Not PR spin - real conversations about capital allocation, clinical strategy, competitive positioning, and how they’re building value.
That’s the edge. Going deeper than a 10-K. Talking to the people actually running these businesses.
The world might be falling apart…
But somewhere in the wreckage, there’s a $50 million market cap healthcare company with a platform technology, a fortress balance sheet, and a management team that owns 30% of the equity.
The market hasn’t noticed yet.
That’s what this page is for.
If you’ve been following along and want full access to the research, this is the time to join.
Thanks for reading,
Nico
Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of The Clinical Edge. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.